PPD signed on as preferred provider for Harbour BioMed

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/tadamichi)
(Image: Getty/tadamichi)
Harbour BioMed has selected PPD as its preferred CRO partner as part of a strategic collaboration to develop novel oncology and immunology therapeutics.

The a global clinical-stage biopharmaceutical company Harbour BioMed (HBM), and contract research organization (CRO), PPD, have today announced a strategic collaboration.

As per the agreement, HBM has selected PPD as its preferred CRO partner to conduct global clinical studies. The companies have worked together previously, recently completing an Australian ethics committee (EC) submission for HBM4003, HBM’s anti-cancer immunotherapy targeting solid tumors.

“Harbour BioMed is leveraging the services of PPD Biotech, which combines the global capabilities of PPD with the hands-on approach, dedication and innovative mindset that drive the success of biotech clients,” ​said Anshul Thakral, executive vice president and global head of PPD Biotech.

“Harbour BioMed’s selection of PPD Biotech as its preferred partner is further evidence that pairing our unique biotech perspective with our scalable global development services is a powerful combination for our customers,”​ he added.

Established in late 2016, HBM’s portfolio includes five clinical-stage, in-licensed compounds as well as therapeutics generated by its internal discovery efforts.  The company also has co-discovery and development collaborations in place with academic institutions and biopharmaceutical companies.

These programs leverage HMB’s two patented transgenic mouse platforms for generating fully human monoclonal antibodies (mAb), which the company also licenses out.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars